Table 1.
Clinicopathological characteristics of all patients (N = 1,237).
Fig 1.
Analyses of correlation between inflammatory marker metrics and their prognostic ability for OS over time.
(A) Pearson product-moment correlation coefficients (r) between inflammatory markers in tabular and graphic representation. (B) The transition in AUC of ROC curve analyses of inflammatory markers for OS according to time after surgery. The table shows AUC data for each inflammatory metric and year after surgery. Alb, albumin; CRP, C-reactive protein; dNLR, derived neutrophil-lymphocyte ratio; LDH, lactate dehydrogenase; LMR, lymphocyte-monocyte ratio; NLR, neutrophil-lymphocyte ratio; PLR, platelet-lymphocyte ratio.
Fig 2.
Associations between inflammatory markers and clinical factors.
The panels show the levels of each inflammatory marker (mean ± standard error) grouped according to the clinical factors. (A) Alb (g/dL), (B) CRP (mg/dL), (C) LDH (U/L), (D) NLR, (E) LMR, (F) PLR, and (G) dNLR. Age, < 75 vs ≥ 75; Sex, Female vs Male; Smoking, Never-smoker vs Smoker; Left or right, Left vs Right; Upper or others, Upper vs Others; Histology, Sq vs Non-Sq; Pathological stage, I vs II or III. P values were calculated with Student’s t-test. Alb, albumin; CRP, C-reactive protein; dNLR, derived neutrophil-lymphocyte ratio; LDH, lactate dehydrogenase; LMR, lymphocyte-monocyte ratio; NLR, neutrophil-lymphocyte ratio; PLR, platelet-lymphocyte ratio.
Table 2.
Multivariate analyses of clinical factor associations with DFS and OS (N = 1,237), showing hazard ratios (HR) with associated confidence intervals (CI) for DFS and OS and their significance for each factor.
Fig 3.
The LMR:LDH ratio as a prognostic indicator in NSCLC.
(A) The transition in the AUC of ROC curve analyses for OS over time after surgery for LMR/LDH. (B) Kaplan–Meier curves showing survival of the patients according to LMR/LDH for DFS and for OS (C). LDH, lactate dehydrogenase; LMR, lymphocyte-monocyte ratio.
Fig 4.
Subset analyses of the relationship between DFS and inflammatory markers, according to clinical factors.
Data are presented as forest plots, with hazard ratios (HR), associated confidence intervals (CI) and p-values for each group. Data for each inflammatory marker appears in a separate panel, as follows (with cut-off level); (A) Alb (g/dL); ≥ 3.5/< 3.5, (B) CRP (mg/dL); ≥ 0.3/< 0.3, (C) LDH (U/L); ≥ 222/< 222, (D) NLR; ≥ 2.56/< 2.56, (E) LMR; ≥ 5.11/< 5.11, (F) PLR; ≥ 164/< 164, (G) dNLR; ≥ 1.92/< 1.92, and (H) LMR/LDH (%); ≥ 2.91/< 2.91. Alb, albumin; CRP, C-reactive protein; dNLR, derived neutrophil-lymphocyte ratio; LDH, lactate dehydrogenase; LMR, lymphocyte-monocyte ratio; NLR, neutrophil-lymphocyte ratio; PLR, platelet-lymphocyte ratio.
Fig 5.
Subset analyses of the relationship between OS and inflammatory markers, according to clinical factors.
Data are presented as forest plots, with hazard ratios (HR), associated confidence intervals (CI) and p-values for each group. Data for each inflammatory marker appears in a separate panel, as follows (with cut-off level); (A) Alb (g/dL); ≥ 3.5/< 3.5, (B) CRP (mg/dL); ≥ 0.3/< 0.3, (C) LDH (U/L); ≥ 222/< 222, (D) NLR; ≥ 2.56/< 2.56, (E) LMR; ≥ 5.11/< 5.11, (F) PLR; ≥ 164/< 164, (G) dNLR; ≥ 1.92/< 1.92, and (H) LMR/LDH (%); ≥ 2.91/< 2.91. Alb, albumin; CRP, C-reactive protein; dNLR, derived neutrophil-lymphocyte ratio; LDH, lactate dehydrogenase; LMR, lymphocyte-monocyte ratio; NLR, neutrophil-lymphocyte ratio; PLR, platelet-lymphocyte ratio.